Clinical trials with less-stringent inclusion criteria and more representative of patients in clinical practice (e.g., patients with comorbidities, non-adherence, polypharmacy), are also needed to comprehensively understand therapy effectiveness and translate the results of such trials into the clinic
Rebouche CJ, Mack DL, Edmonson PF
This makes it a popular addition to cutting phases or recomposition protocols As noted by Molitch in the Journal of Clinical Endocrinology & Metabolism , growth hormone secretagogues like Ipamorelin can improve body composition by promoting fat oxidation and reducing visceral adiposity (Molitch, JCEM)
When intra-portal insulin levels are increased (e.g., obesity, Cushings syndrome, or due to treatment with glucocorticoids and glucagon-like peptide 1 receptor agonists) or decreased (e.g., malnutrition, anorexia nervosa and type 1 diabetes mellitus), these changes secondarily alter hepatic GH sensitivity resulting in a secondary association with discordant GH and IGF-I levels (e.g., high GH/low IGF-I levels or low GH/high IGF-I levels, respectively)
